Another biotech buy for Roche

Written byMegan Scudellari

| 1 min read

After making a $43.7 billion offer linkurl:yesterday;http://www.the-scientist.com/blog/display/54841/ (July 21) to buy the 44% of Genentech stock it didn't already own, the Swiss pharmaceutical company announced another biotech purchase today. Roche will acquire linkurl:Mirus Bio Corporation;http://www.mirusbio.com/ for $125 million. Roche's half-year financial linkurl:results,;http://www.roche.com/home/figures/fig_halfyearrep_2008.htm released on Monday but eclipsed by the Genentech offer, showed a six percent decline in pharmaceutical sales. Roche intends to borrow half the funds required for the Genentech takeover, according to a report published Monday by Global Insight pharmaceutical analyst Gaelle Marinoni, which "implies that the Swiss giant is keeping its options and cash stash open for further smaller acquisitions." Mirus, one of those smaller acquisitions, is a private US-owned company based in Madison, Wisconsin that specializes in RNA interference (RNAi) technologies. Their products include nucleic acid reagents, kits, and protocols, and the company has siRNA delivery platforms in the pipeline. This is not Roche's first move toward linkurl:RNAi;http://www.the-scientist.com/article/display/18847/ therapeutics: last year, Roche struck a deal linkurl:Alnylam Pharmaceuticals Inc.,;http://www.the-scientist.com/blog/display/54395/ a German company, for the rights to their RNAi technology, an alliance the companies claimed to be worth $1 billion. "The race is on" for successful use of the RNAi technology, according to a Global Insight analysis, "and any breakthrough could prove very lucrative." Roche plans to maintain Mirus's research station in Madison. The takeover is scheduled to be completed by the end of the year. Meanwhile, Genentech and Roche leaders met today to informally discuss the buyout, but some analysts are expecting that Roche will to have to increase its offer to take over the biotech giant. The offer is at $89 a share, but Genentech stock jumped to $92.91 by the end of the day on Monday, a possible sign that investors expect a raise on the offer, according to linkurl:the Associated Press.;http://www.iht.com/articles/ap/2008/07/22/business/EU-Switzerland-Roche-Genentech.php

Another biotech buy for Roche

The Scientist ARCHIVES

Become a Member of

Meet the Author

Megan Scudellari

Related Research Resources

What Is the Amniotic Fluid Composed of?

Research Resources

Podcasts

Webinars

Videos

Infographics

eBooks

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Skip the Wait for Protein Stability Data with Aunty

An Automated DNA-to-Data Framework for Production-Scale Sequencing

Products

Product News

Nuclera eProtein Discovery System installed at leading Universities in Taiwan

BRANDTECH Scientific Introduces the Transferpette® pro Micropipette: A New Twist on Comfort and Control

Biotium Launches GlycoLiner™ Cell Surface Glycoprotein Labeling Kits for Rapid and Selective Cell Surface Imaging

Thermo Scientific X and S Series General Purpose Centrifuges